Glaucoma Clinical Trial
Official title:
Comparison Between an Electronic Mobile Device(DEM) and Optical Coherence Tomography (OCT) to Determine Cup-to-disc Ratio (C/D) Through a Non-inferiority Trial With Masked Data Analysis
This study was a non-inferiority trial with masked data analysis. Individuals ranging from 18 to 60 years from both genders that met the pre-defined criteria were included. This study was carried out in Recife at Clinica Oftalmologica Zona Sul and at Centro de Informatica-UFPE. Using both equipment, 5 vertical cup-to-disc ratio (VCDR) evaluations were performed for each eye of the individuals, under midriatic conditions. Evaluations were done by examiners who did not know previously results obtained from other equipment. Data was collected by the main researcher of this research. This study was approved by the ethics committee before it started and all research members signed the TCLE agreement. The statistical test employed in this study was Pearson Correlation test.
Glaucoma is the second major cause of blindness in the world, lagging only behind cataract.
However, unlike cataract, blindness caused by glaucoma is irreversible. Early diagnosis of
the disease and progression monitoring is thus essential for proper treatment in order to
avoid irreversible blindness. The most common screening exam for glaucoma diagnosis and
monitoring is the eye fundus evaluation where Cup-to-Disc ratio (CDR) among other parameters
are assessed. This kind of evaluation is performed by ophthalmologists based on their visual
perception, requiring not only specific training but also some significant amount of time of
eye examination.Objective measurement of CDR involves high cost equipment which in turn
requires some specific training in order to use them. Currently, the Optical Coherence
Tomography is used as the gold standard for CDR measurement. An OCT exam uses a high cost
and complex equipment that most of the time is not affordable for low-income people. This
study proposes a portable electronic device that captures eye fundus images, analyzes these
images, performs CDR calculation and allows storing these images for further analysis. This
low cost and portable device was developed to be used in several health services (public or
private) and has low energy consumption, easing its mobility. Moreover, using this device is
easy, not requiring any significant learning effort from ophthalmologists. In developing
countries where screening programs for early diagnosis of glaucomatous neuropathy are
adopted, an ever-growing number of researchers are putting a significant amount of effort to
develop cost-benefit solutions that can reach low-income people and remote areas.
Objective: This study compared CDR measurements from the portable electronic device (PED)
developed by Centro de Informatica da Universidade Federal de Pernambuco to CDR measurements
provided by OCT.
Methods:This study was a non-inferiority trial with masked data analysis. Individuals
ranging from 18 to 60 years from both genders that met the pre-defined criteria were
included. This study was carried out in Recife at Clinica Oftalmologica Zona Sul and at
Centro de Informatica-UFPE. Using both equipment, 5 vertical cup-to-disc ratio (VCDR)
evaluations were performed for each eye of the individuals, under midriatic conditions.
Evaluations were done by examiners who did not know previously results obtained from other
equipment. Data was collected by the main researcher of this research. This study was
approved by the ethics committee before it started and all research members signed the TCLE
agreement. The statistical test employed in this study was Pearson Correlation test.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 |